A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation

NCT06081829 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Cholangiocarcinoma Non-resectable
Cholangiocarcinoma Metastatic

Interventions

DRUG: Ivosidenib

Sponsor

Servier